Table 1. Select Immunotherapy Agents and Ongoing
Immunotherapy Clinical Trials in RCC
Ongoing clinical trials for checkpoint inhibitors
Trial
Clinical trial
iden fier Status Disease se ng
Neoadjuvant durvalumab ±
tremelimumab
NCT02762006 Recrui ng Neoadjuvant
Neoadjuvant pembrolizumab NCT02212730 Recrui ng Neoadjuvant
Neoadjuvant nivolumab NCT02595918 Recrui ng Neoadjuvant
Neoadjuvant nivolumab NCT02575222 Recrui ng Neoadjuvant
Nivolumab vs. nivolumab +
bevacizumab vs. nivolumab +
ipilimumab
NCT02210117 Recrui ng Neoadjuvant
Nivolumab pre- and post-
surgery
NCT02446860 Recrui ng Neoadjuvant/
adjuvant
Pembrolizumab + RT NCT02318771 Recrui ng Refractory
Nivolumab + salvage
nivolumab + ipilimumab
NCT03117309 Recrui ng Stage IV,
treatment-naive
Pembrolizumab in clear cell
and non-clear cell RCC
KEYNOTE-427
(NCT02853344)
Recrui ng Newly diagnosed
Stage IV or
recurrent disease
Phase Ib/II pembrolizumab +
lenva nib in solid tumors
NCT02501096 Recrui ng solid
tumors including
RCC
Refractory
Pembrolizumab +
bevacizumab
NCT02348008 Ac ve, not
recrui ng
Treatment-naive
Biomarker-driven trial of
nivolumab vs. nivolumab +
ipilimumab vs. suni nib or
pazopanib
BIONIKK
(NCT02960906)
Not yet
recrui ng
Refractory
Suni nib-avelumab vs.
avelumab-suni nib
NCT03035630 Not yet
recrui ng
Refractory
Ongoing clinical trials with HD IL-2
Trial
Clinical trial
iden fier Status
HD IL-2 + HQ NCT01550367 Recrui ng
HD IL-2 ± SBRT NCT02306954 Recrui ng
HD IL-2 ± RT NCT01896271 Recrui ng
HD IL-2 + pembrolizumab NCT02964078 Recrui ng
PROCLAIM NCT01415167 Registry of HD IL-2 pa ents
HD IL-2 + en nostat NCT01038778 Ongoing, presented 2016
